136 related articles for article (PubMed ID: 10450686)
1. Implications of nonuniform tumor doses for radioimmunotherapy.
O'Donoghue JA
J Nucl Med; 1999 Aug; 40(8):1337-41. PubMed ID: 10450686
[TBL] [Abstract][Full Text] [Related]
2. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.
O'Donoghue JA; Sgouros G; Divgi CR; Humm JL
J Nucl Med; 2000 Mar; 41(3):538-47. PubMed ID: 10716330
[TBL] [Abstract][Full Text] [Related]
3. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.
O'Donoghue JA; Bardiès M; Wheldon TE
J Nucl Med; 1995 Oct; 36(10):1902-9. PubMed ID: 7562062
[TBL] [Abstract][Full Text] [Related]
4. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.
Howell RW; Goddu SM; Rao DV
J Nucl Med; 1994 Nov; 35(11):1861-9. PubMed ID: 7965170
[TBL] [Abstract][Full Text] [Related]
5. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
6. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
[TBL] [Abstract][Full Text] [Related]
7. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
8. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
Wessels BW; Syh JH; Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
[TBL] [Abstract][Full Text] [Related]
9. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
Bao A; Zhao X; Phillips WT; Woolley FR; Otto RA; Goins B; Hevezi JM
Med Phys; 2005 Jan; 32(1):200-8. PubMed ID: 15719971
[TBL] [Abstract][Full Text] [Related]
10. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
11. Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity.
Sparks RB; Crowe EA; Wong FC; Toohey RE; Siegel JA
J Nucl Med; 2002 Aug; 43(8):1110-4. PubMed ID: 12163638
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging.
Flux GD; Webb S; Ott RJ; Chittenden SJ; Thomas R
J Nucl Med; 1997 Jul; 38(7):1059-66. PubMed ID: 9225791
[TBL] [Abstract][Full Text] [Related]
14. [Nonuniform dose distributions in normal body organs and tissues in the radiotherapy of malignant tumors].
Klepper LIa
Med Tekh; 1999; (5):6-10. PubMed ID: 10560087
[TBL] [Abstract][Full Text] [Related]
15. Internal dosimetry using data derived from autoradiographs.
Humm JL; Macklis RM; Bump K; Cobb LM; Chin LM
J Nucl Med; 1993 Oct; 34(10):1811-7. PubMed ID: 8410302
[TBL] [Abstract][Full Text] [Related]
16. Application of the linear-quadratic model to combined modality radiotherapy.
Bodey RK; Evans PM; Flux GD
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):228-41. PubMed ID: 15093920
[TBL] [Abstract][Full Text] [Related]
17. Generalized approach to absorbed dose calculations for dynamic tumor and organ masses.
Goddu SM; Howell RW; Rao DV
J Nucl Med; 1995 Oct; 36(10):1923-7. PubMed ID: 7562065
[TBL] [Abstract][Full Text] [Related]
18. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
[TBL] [Abstract][Full Text] [Related]
19. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
Leichner PK; Kwok CS
Med Phys; 1993; 20(2 Pt 2):529-34. PubMed ID: 8492761
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
